Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID06661655

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

Led by E-Scopics · Updated on 2025-08-15

120

Participants Needed

3

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating an ultraportable ultrasound device called Hepatoscope for non-invasive assessment of liver fat (hepatic steatosis) in patients with metabolic dysfunction-associated liver diseases (MASLD and MASH). The study compares Hepatoscope's measurements to current diagnostic methods like MRI-PDFF, aiming to assess how well the device measures liver fat and stiffness. This research is sponsored by E-Scopics and focuses on patients with fatty liver conditions related to metabolic syndrome. Participants will undergo an ultrasound exam using the Hepatoscope device to collect quantitative data related to liver steatosis severity. The device measures ultrasound attenuation, backscattering coefficient, and sound speed. The study compares these ultrasound parameters to liver fat fraction measured by MRI-PDFF and also evaluates comparisons with FibroScan and magnetic resonance elastography (MRE) for liver stiffness. Some patients may also have liver biopsy results for further comparison. During the study, participants will receive the Hepatoscope ultrasound exam and have their measurements compared with MRI-PDFF within six months of enrollment. Other evaluations include FibroScan and MRE comparisons. The study involves written consent, ongoing social security coverage, and monitoring for safety and accuracy. The total participation timeline and follow-up procedures align with the imaging and clinical assessments conducted within this period.

CONDITIONS

Brief Title

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patient below 80 years old
  • Patients with MASLD or MASH recruited in interventional trials requiring MRI PDFF +/- MRE per protocol
  • Patients with MASLD or MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per protocol
  • Patients referred to MRI-PDFF or MRE
  • Patients who have given written consent to participate
  • Patients with ongoing social security coverage
Not Eligible

You will not qualify if you...

  • Patients younger than 18 years or older than 80 years
  • Patients with active implants
  • Patients with wounds in the right upper quadrant of the abdomen where the Hepatoscope exam is performed
  • Patients with a history of decompensated cirrhosis
  • Patients with a history of hepatocellular carcinoma
  • Adults under tutorship or unable to provide informed consent
  • Pregnant or breastfeeding patients
  • Persons deprived of liberty
  • Patients hospitalized without consent or in an emergency
  • Patients with another known liver disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 6 months from enrollment

Participants undergo ultrasound exams with the Hepatoscope device to collect quantitative measurements related to liver steatosis. These measurements are compared with MRI PDFF, FibroScan, and MRE results as part of the diagnostic assessment.

1 to 2 visits depending on imaging schedules

Trial Site Locations

Total: 3 locations

1

University Hospital Angers

Angers, France, 49933

Actively Recruiting

2

Beaujon University Hospital

Clichy, France, 92110

Actively Recruiting

3

Pitie Salpetriere University Hospital

Paris, France, 75013

Not Yet Recruiting

Loading map...

Research Team

J

Jerome Boursier, MD, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Stud...

NASH - Nonalcoholic Steatohepatitis

Actively Recruiting

322 locations

Chiglitazar in Combination With Anti-Inflammatory and Hepato...

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Actively Recruiting

17 locations

A Phase 2a, Double-blind, 4-arm Trial Evaluating Safety, Exp...

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Actively Recruiting

31 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here